DALLAS, April 6, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Inspire Pharmaceuticals Inc. (Nasdaq:ISPH). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at:
Inspire Pharmaceuticals Inc. (ISPH) is a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Its strategy is to create a sustainable portfolio of products by leveraging its commercial capabilities and pipeline assets and pursuing corporate development and licensing opportunities. The Company's specialty eye care sales force generates revenue from the promotion of Azasite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis. The Company receives royalties based on net sales of Restasis (cyclosporine ophthalmic emulsion) 0.05% and Diquas Ophthalmic Solution 3% (diquafosol tetrasodium) in Japan. In 2010, the company generated double digit revenue growth for the sixth consecutive year from its eye care business, driven by a 36% increase in Azasite prescriptions, continued Elestat sales and Restasis royalties.
This newsletter has been helping traders make great investment decisions on ISPH; click here for a 25% discount offer.
In the report, the analyst notes:
"Shares of ISPH traded higher yesterday on news that it would be acquired by Merck for $430 million. The deal, which is expected to expand Merck's ophthalmology business, values ISPH at $5 per share, marking a 26% premium to the stock's closing price on Monday."
"ISPH's key product is Azasite, which is a treatment for pinkeye cause by bacteria. It also receives royalties on sales of Allergan Inc.'s dry-eye drug Restasis. Azasite had $42.7 million in revenue in 2010, an increase of 22% compared to $35.0 million recognized in 2009."
To read the entire report visit:
See what investors are saying about ISPH at
Get breaking news on ISPH at
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
CONTACT: Brian Johnson firstname.lastname@example.org 1-888-307-2850